Solvonis Therapeutics plc (GB:SVNS)
LSE:SVNS
Want to see GB:SVNS full AI Analyst Report?
SVNS Stock Chart & Stats
0.35 p
--
Market closed
0.35 p
--
Day’s Range― - ―
52-Week Range0.13 p - 0.40 p
Previous CloseN/A
VolumeN/A
Average Volume (3M)34.43M
Market Cap
£16.68M
Enterprise Value15.03M
Total Cash (Recent Filing)£757.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.83
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding6,806,403,300
10 Day Avg. Volume23,401,787
30 Day Avg. Volume34,434,652
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt materially reduces solvency risk and preserves financial flexibility over months. With low interest obligations the company can prioritize operational restructuring or targeted investment without immediate refinancing pressure, extending runway during a turnaround.
Growing Equity BaseAn expanding equity position provides a cushion against future losses and supports near-term solvency. This stronger capital base improves ability to absorb further operating deficits and increases optionality for non-debt financing or strategic reinvestment over the medium term.
Lean Operating FootprintA very small headcount implies a low fixed-cost structure, which can materially extend cash runway and allow management to pivot product or go-to-market plans without heavy payroll commitments. That lean base helps preserve capital while repositioning the business.
Bears Say
Recurring Operating/net LossesSustained operating and net losses erode capital and limit internal funding for growth. Over months this reduces reinvestment capacity, pressures margins if revenues falter, and increases reliance on external financing, complicating any long-term recovery plan.
Revenue Collapse To Near-zeroA near-zero revenue base undermines the company's ability to achieve scale or validate its business model. Without recurring sales, margin recovery is impossible and the firm becomes dependent on capital injections, raising sustainability risk over the medium term.
Persistent Cash BurnOngoing negative operating and free cash flows deplete resources and force external funding or asset sales. Over a 2–6 month horizon this increases dilution or refinancing risk and constrains the company's ability to invest in product development or commercialization.
Solvonis Therapeutics News
SVNS FAQ
What was Solvonis Therapeutics plc’s price range in the past 12 months?
Solvonis Therapeutics plc lowest share price was 0.13 p and its highest was 0.40 p in the past 12 months.
What is Solvonis Therapeutics plc’s market cap?
Solvonis Therapeutics plc’s market cap is £16.68M.
When is Solvonis Therapeutics plc’s upcoming earnings report date?
Solvonis Therapeutics plc’s upcoming earnings report date is Sep 24, 2026 which is in 121 days.
How were Solvonis Therapeutics plc’s earnings last quarter?
Solvonis Therapeutics plc released its earnings results on Apr 29, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Solvonis Therapeutics plc overvalued?
According to Wall Street analysts Solvonis Therapeutics plc’s price is currently Overvalued.
Does Solvonis Therapeutics plc pay dividends?
Solvonis Therapeutics plc does not currently pay dividends.
What is Solvonis Therapeutics plc’s EPS estimate?
Solvonis Therapeutics plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics plc have?
Solvonis Therapeutics plc has 6,806,403,300 shares outstanding.
What happened to Solvonis Therapeutics plc’s price movement after its last earnings report?
Solvonis Therapeutics plc reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.781%.
Which hedge fund is a major shareholder of Solvonis Therapeutics plc?
Currently, no hedge funds are holding shares in GB:SVNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics plc
Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds. In addition, the company offers GRAFTALLOY, a line of polymer-polymer nano-alloys to increase abrasion and temperature resistance, and impact strength, as well as reduce friction coefficient; GRAFTASYNT, a line of synthetic products comprising halogen-free flame retardants; and GRAFTAMER, a thermo-reversible crosslinking, self-hardening, and self-healing smart polymer with shape memory, etc. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Technical Analysis
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―
Options Prices
Currently, No data available
---